Advertisement

Für Sie Gelesen: Internationale Fachliteratur

  • R. Stefan Roß
Chapter

Zusammenfassung

Interferon kann die virale Replikation auf vielfältige Weise hemmen. Zu den Mechanismen der Interferonwirkung gehören beispielsweise die Freisetzung von Zytokinen und die Induktion zellulärer Proteine wie 2’, 5’-Oligoadenylat-Synthetasen, Phosphodiesterase, MxA-Protein und Proteinkinase R (PKR) [1]. Die PKR wird durch doppelsträngige, virale RNA aktiviert und kann nach einer Autophosphorylierung ihrerseits den eukaryotischen Initiationsfaktor 2 (eIF2) phosphorylieren, was zu einer Inhibition der zellulären Proteinsynthese und damit zu einer Hemmung der viralen Replikation führt (Abb. 1). Zwei kürzlich erschienene Untersuchungen beschäftigen sich mit der Interaktion zwischen der PKR und einzelnen Proteinen des Hepatitis-C-Virus (HCV) [2,3].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Hammer SM, Inouye RT (1997) Antiviral agents. In: Richman DD, Whitley RJ, Hayden FD (Hrsg.) Clinical virology. New York: Churchill Livingstone, 185–250.Google Scholar
  2. 2.
    Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM (1999) Inhibition of interferon induci-ble protein kinase PKR by HCV E2 protein. Science 285: 107–110.PubMedCrossRefGoogle Scholar
  3. 3.
    Gale M, Kwieciszewski B, Dosset M, Nakao H, Katze MG (1999) Antiapoptotic and oncoge-nic potentials of hepatitis C virus are linked to interferon resistance by viral repression of PKR protein kinase. J Virol 73: 6506–6516.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Gale M, Korth MJ, Tang MN, Tan S-L, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze (1999) Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by non-structural 5A protein. Virology 230: 217–227.CrossRefGoogle Scholar
  5. Lohmann V, Körner F, Koch J-O, Herian U, Theilmann L, Bartenschlager R (1999) Replication of sub-genomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110–113.PubMedCrossRefGoogle Scholar
  6. Otten RA, Ellenberger DL, Adams DR, Fridlund CA, Jackson E, Pieniazek D, Rayfield MA (1999) Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. J Inf Dis 180: 673–684.CrossRefGoogle Scholar
  7. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC (1999) Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Inf Dis 180: 666–672.CrossRefGoogle Scholar
  8. 1.
    Morris AA, Carr A (1999) HIV nucleoside analogues: new adverse effects on mitochondria? Lancet 354: 1046–1047.PubMedCrossRefGoogle Scholar
  9. 2.
    Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, et al. (1999) A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13: 1359–1367.CrossRefGoogle Scholar
  10. 3.
    Brinkman K, Smeitink JA, Romijn JA, Reiss P (1999) (Hypothesis) Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112–1115.PubMedCrossRefGoogle Scholar
  11. 4.
    Culane M, Foweler MG, Lee SS, et al. (1999) Lack of long term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 281: 151–157.CrossRefGoogle Scholar
  12. 5.
    Blanche S, Tardieu M, Rustin P, Slama A, et al. (1999) Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354: 1084–1089.PubMedCrossRefGoogle Scholar
  13. 1.
    Profit L, Eagling VA, Back DJ (1999) Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13: 1623–1627.PubMedCrossRefGoogle Scholar
  14. 2.
    Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A (1999) MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nature Med 5: 1048–1051.PubMedCrossRefGoogle Scholar
  15. Swingler S, Mann A, Jacqué J-M, Brichacek B, et al. (1999) HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nature Med 5: 997–1003.PubMedCrossRefGoogle Scholar
  16. Cassone A, De Bernardis F, Torosantucci A, et al. (1999) In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Inf Dis 180: 448–453.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • R. Stefan Roß
    • 1
  1. 1.Institut für Virologie, Nationales Referenzzentrum für Hepatitis CUniversitätsklinikum EssenEssenDeutschland

Personalised recommendations